Hansoh Pharma (03692): XynQ (Ina-Rilizumab Injection) obtained the National Medical Products Administration certificate for the third indication.

20:22 27/03/2026

Hanson Pharmaceuticals (03692) announced that on March 25, 2026, the innovative drug Xin Yue (inelizumab injection) was granted a drug registration certificate by the National Medical Products Administration of China (NMPA), approving an additional indication: the drug in combination with conventional therapy is used to treat adult generalized myasthenia gravis (gMG) patients who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This is the third indication approved for Xin Yue.

Hansoh Pharma (03692) announced that on March 25, 2026, the innovative drug Xinyue (Inalizumab Monoantibody Injection) has been granted a drug registration certificate by the National Medical Products Administration(NMPA) of China. It has been approved for an additional indication: the product, in combination with conventional treatment drugs, is used to treat adult generalized myasthenia gravis (gMG) patients who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This is the third indication approved for Xinyue.

MAIYUE TECH (02501) appoints Guan Xiongjun as company secretary.

KIN PANG HLDGS (01722) announced annual results with a net loss of 19.777 million Macau dollars, an increase of 11.79% compared to the previous year.

MAIYUE TECH (02501) released its annual performance results, with a net profit attributable to shareholders of 5.697 million yuan, an increase of 1215.7% compared to the previous year.

MAIYUE TECH (02501) appoints Guan Xiongjun as company secretary.

KIN PANG HLDGS (01722) announced annual results with a net loss of 19.777 million Macau dollars, an increase of 11.79% compared to the previous year.

MAIYUE TECH (02501) released its annual performance results, with a net profit attributable to shareholders of 5.697 million yuan, an increase of 1215.7% compared to the previous year.